1.83

0.55% 0.01

After Hours: 1.84 0.01 +0.55%

Caribou Biosciences Inc (CRBU)

Overview News Price History Option Chain Financials Why CRBU Down? Discussions Forecast

Caribou Biosciences Inc stock is traded at $1.83, with a volume of 1.09M. It is up +0.55% in the last 24 hours and down -4.69% over the past month. Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.

Previous Close:

$1.82

Open:

$1.83

24h Volume:

1.09M

Relative Volume:

0.59

Market Cap:

$181.50M

Revenue:

$11.16M

Net Income/Loss:

$-148.13M

P/E Ratio:

-1.152

EPS:

-1.5885

Net Cash Flow:

$-112.35M

1W Performance:

+3.39%

1M Performance:

-4.69%

6M Performance:

+6.40%

1Y Performance:

+33.58%

1-Day Range:

$1.80

$1.85

1-Week Range:

$1.725

$1.92

52-Week Range:

$1.335

$3.535

Caribou Biosciences Inc Stock (CRBU) Company Profile

Name

Caribou Biosciences Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

510-982-6030

Address

2929 7TH STREET, SUITE 105, BERKELEY

Employee

Twitter

Next Earnings Date

2026-08-11

Latest SEC Filings

CRBU's Discussions on Twitter

Compare CRBU vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CRBU Caribou Biosciences Inc	1.83	174.56M	11.16M	-148.13M	-112.35M	-1.5885
VRTX Vertex Pharmaceuticals Inc	529.59	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	649.81	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	916.80	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.04	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.99	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Caribou Biosciences Inc Stock (CRBU) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-03-24	Downgrade	Evercore ISI	Outperform → In-line
Nov-08-23	Initiated	Cantor Fitzgerald	Neutral
Oct-31-23	Initiated	Evercore ISI	Outperform
Jul-11-23	Initiated	Truist	Buy
Feb-18-22	Initiated	RBC Capital Mkts	Outperform
Dec-01-21	Initiated	Oppenheimer	Outperform
Nov-30-21	Initiated	H.C. Wainwright	Buy
Nov-15-21	Upgrade	Citigroup	Neutral → Buy
Aug-17-21	Initiated	BofA Securities	Buy
Aug-17-21	Initiated	Citigroup	Neutral
Aug-17-21	Initiated	SVB Leerink	Outperform

View All

Caribou Biosciences Inc Stock (CRBU) Latest News

Jun 29, 2026

Caribou Biosciences, Inc.(NasdaqGS: CRBU) added to Russell 2000 Index - marketscreener.com

Jun 29, 2026

Caribou Biosciences, Inc.(NasdaqGS:CRBU) added to Russell Microcap Value Benchmark Index - marketscreener.com

Jun 29, 2026

Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - Investing News Network

Jun 29, 2026

Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - GlobeNewswire Inc.

Jun 29, 2026

Caribou Biosciences, Inc.(NasdaqGS: CRBU) added to Russell Microcap Index - marketscreener.com

Jun 29, 2026

Jun 28, 2026

Caribou Biosciences, Inc.(NasdaqGS: CRBU) added to Russell 3000E Index - marketscreener.com

Jun 28, 2026

CRBUCaribou Biosciences Inc Latest SEC Filings - Finviz

Jun 28, 2026

Bronstein, Gewirtz & Grossman, LLC Encourages Caribou Biosciences - The National Law Review

Jun 28, 2026

Jun 27, 2026